Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump’s push to onshore pharmaceutical manufacturing.
U.S. President Donald Trump’s executive order on drug pricing threatens Roche’s planned $50 billion investment in the United States, the company said on Wednesday.
